San Diego, California-based Mast Therapeutics Inc. is pinning its hopes on its vasodilating AIR001 program for heart failure following the second Phase III failure for its sickle cell disease candidate vepoloxamer.
Mast’s share price on the NYSE plummeted to $0.11 on the morning of Sept. 21 following the announcement made late on Sept. 20. The Phase III EPIC study missed its primary endpoint of a significant reduction in the mean duration of vaso-occlusive crisis (VOC) compared with placebo in sickle cell disease patients
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?